Fennec Pharmaceuticals (FENC) Stock Forecast, Price Target & Predictions
FENC Stock Forecast
Fennec Pharmaceuticals stock forecast is as follows: an average price target of $15.75 (represents a 239.44% upside from FENC’s last price of $4.64) and a rating consensus of 'Buy', based on 12 wall street analysts offering a 1-year stock forecast.
FENC Price Target
The average price target for Fennec Pharmaceuticals (FENC) is $15.75 based on 1-year price targets from 12 Wall Street analysts in the past 3 months, with a price target range of $19.00 to $12.00. This represents a potential 239.44% upside from FENC's last price of $4.64.
FENC Analyst Ratings
According to 12 Wall Street analysts, Fennec Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for FENC stock is 0 'Strong Buy' (0.00%), 11 'Buy' (91.67%), 1 'Hold' (8.33%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Fennec Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| May 15, 2024 | Chase Knickerbocker | Craig-Hallum | $17.00 | $7.34 | 131.61% | 266.38% |
| May 15, 2024 | Raghuram Selvaraju | H.C. Wainwright | $15.00 | $7.03 | 113.37% | 223.28% |
| Apr 04, 2024 | Raghuram Selvaraju | H.C. Wainwright | $18.00 | $10.77 | 67.13% | 287.93% |
| Mar 19, 2024 | Chase Knickerbocker | Craig-Hallum | $18.00 | $11.01 | 63.49% | 287.93% |
| Nov 22, 2022 | - | Cantor Fitzgerald | $12.00 | $9.17 | 30.86% | 158.62% |
| Sep 26, 2022 | - | Wedbush | $19.00 | $7.11 | 167.23% | 309.48% |
The latest Fennec Pharmaceuticals stock forecast, released on May 15, 2024 by Chase Knickerbocker from Craig-Hallum, set a price target of $17.00, which represents a 131.61% increase from the stock price at the time of the forecast ($7.34), and a 266.38% increase from FENC last price ($4.64).
Fennec Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 4 |
| Avg Price Target | - | - | $17.00 |
| Last Closing Price | $4.64 | $4.64 | $4.64 |
| Upside/Downside | -100.00% | -100.00% | 266.38% |
In the current month, the average price target of Fennec Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Fennec Pharmaceuticals's last price of $4.64. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| May 15, 2024 | Craig-Hallum | Buy | Buy | Hold |
| May 15, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Apr 04, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Nov 22, 2022 | Cantor Fitzgerald | - | Overweight | Upgrade |
| Sep 26, 2022 | Wedbush | Outperform | Outperform | Hold |
| Sep 07, 2022 | JonesTrading | - | Buy | Initialise |
| Sep 07, 2022 | Oppenheimer | - | Outperform | Initialise |
| Sep 07, 2022 | Morgan Stanley | - | Equal-Weight | Initialise |
| Sep 07, 2022 | Jefferies | - | Buy | Initialise |
| Sep 07, 2022 | Needham | - | Buy | Initialise |
Fennec Pharmaceuticals's last stock rating was published by Craig-Hallum on May 15, 2024. The company gave FENC a "Buy" rating, the same as its previous rate.
Fennec Pharmaceuticals Financial Forecast
Fennec Pharmaceuticals Revenue Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $10.00M | $6.51M | $3.33M | $1.68M | $1.53M | - |
| Avg Forecast | $21.03M | $20.25M | $18.69M | $17.91M | $15.77M | $15.18M | $14.01M | $13.43M | $14.23M | $17.59M | $10.59M | $9.27M | $9.07M | $8.99M | $11.05M | $10.21M | $8.66M | $5.33M | $3.72M | $1.84M | $893.80K | $50.00M |
| High Forecast | $24.16M | $23.27M | $21.48M | $20.58M | $18.11M | $17.44M | $16.10M | $15.43M | $16.35M | $20.21M | $12.17M | $10.98M | $11.61M | $10.32M | $11.05M | $10.21M | $9.95M | $5.37M | $4.28M | $2.12M | $1.03M | $50.00M |
| Low Forecast | $17.91M | $17.25M | $15.92M | $15.26M | $13.43M | $12.93M | $11.94M | $11.44M | $12.12M | $14.98M | $9.02M | $7.56M | $6.52M | $7.65M | $11.05M | $10.21M | $7.38M | $5.29M | $3.17M | $1.57M | $761.21K | $50.00M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.15% | 1.22% | 0.89% | 0.91% | 1.72% | - |
Fennec Pharmaceuticals's average Quarter revenue forecast for Mar 24 based on 1 analysts is $10.21M, with a low forecast of $10.21M, and a high forecast of $10.21M. FENC's average Quarter revenue forecast represents a 2.10% increase compared to the company's last Quarter revenue of $10.00M (Dec 23).
Fennec Pharmaceuticals EBITDA Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-1.87M | $-915.00K | $-4.55M | $-5.16M | $-6.05M | $-4.36M |
| Avg Forecast | $-2.45M | $-2.36M | $-2.18M | $-2.08M | $-1.83M | $-1.77M | $-1.63M | $-1.56M | $-1.66M | $-2.05M | $-1.23M | $-1.08M | $-1.06M | $-1.05M | $-1.29M | $-1.19M | $-1.01M | $-620.02K | $-433.29K | $-214.54K | $-104.00K | $-6.01M |
| High Forecast | $-2.08M | $-2.01M | $-1.85M | $-1.78M | $-1.56M | $-1.50M | $-1.39M | $-1.33M | $-1.41M | $-1.74M | $-1.05M | $-879.94K | $-758.78K | $-890.39K | $-1.29M | $-1.19M | $-858.63K | $-615.41K | $-369.02K | $-182.71K | $-88.57K | $-6.01M |
| Low Forecast | $-2.81M | $-2.71M | $-2.50M | $-2.39M | $-2.11M | $-2.03M | $-1.87M | $-1.80M | $-1.90M | $-2.35M | $-1.42M | $-1.28M | $-1.35M | $-1.20M | $-1.29M | $-1.19M | $-1.16M | $-624.64K | $-497.82K | $-246.49K | $-119.49K | $-6.01M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.85% | 1.48% | 10.50% | 24.06% | 58.19% | 0.73% |
undefined analysts predict FENC's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Fennec Pharmaceuticals's previous annual EBITDA (undefined) of $NaN.
Fennec Pharmaceuticals Net Income Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-2.76M | $-1.87M | $-5.44M | $-7.63M | $-7.79M | $-4.49M |
| Avg Forecast | - | - | - | - | $1.76M | $1.70M | $1.57M | $1.51M | $1.23M | $4.72M | $-1.57M | $-2.67M | $-2.87M | $-2.46M | $-684.27K | $-1.57M | $-492.68K | $-3.28M | $-4.29M | $-5.53M | $-7.25M | $20.40M |
| High Forecast | - | - | - | - | $2.10M | $2.03M | $1.87M | $1.80M | $1.47M | $5.64M | $-1.27M | $-2.26M | $-1.31M | $-1.99M | $-552.32K | $-1.27M | $739.02K | $-2.65M | $-3.46M | $-4.46M | $-5.85M | $20.40M |
| Low Forecast | - | - | - | - | $1.42M | $1.37M | $1.27M | $1.22M | $994.17K | $3.81M | $-1.88M | $-3.08M | $-4.44M | $-2.94M | $-816.75K | $-1.88M | $-2.46M | $-3.92M | $-5.12M | $-6.60M | $-8.66M | $20.40M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 5.59% | 0.57% | 1.27% | 1.38% | 1.07% | -0.22% |
Fennec Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. FENC's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Fennec Pharmaceuticals SG&A Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $11.14M | $7.19M | $7.83M | $6.85M | $7.47M | $3.68M |
| Avg Forecast | $391.47M | $376.97M | $347.98M | $333.48M | $293.48M | $282.61M | $260.87M | $250.02M | $264.95M | $327.46M | $197.14M | $172.62M | $168.80M | $167.26M | $205.63M | $190.14M | $161.29M | $99.19M | $69.32M | $34.32M | $16.64M | $930.75M |
| High Forecast | $449.77M | $433.12M | $399.80M | $383.14M | $337.19M | $324.70M | $299.72M | $287.25M | $304.41M | $376.22M | $226.50M | $204.46M | $216.20M | $192.17M | $205.63M | $190.14M | $185.31M | $99.93M | $79.64M | $39.43M | $19.12M | $930.75M |
| Low Forecast | $333.40M | $321.05M | $296.36M | $284.01M | $249.95M | $240.69M | $222.17M | $212.93M | $225.65M | $278.88M | $167.89M | $140.78M | $121.39M | $142.45M | $205.62M | $190.13M | $137.37M | $98.45M | $59.04M | $29.23M | $14.17M | $930.75M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.07% | 0.07% | 0.11% | 0.20% | 0.45% | 0.00% |
Fennec Pharmaceuticals's average Quarter SG&A projection for Mar 24 is $190.14M, based on 1 Wall Street analysts, with a range of $190.13M to $190.14M. The forecast indicates a 1607.47% rise compared to FENC last annual SG&A of $11.14M (Dec 23).
Fennec Pharmaceuticals EPS Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.10 | $-0.07 | $-0.21 | $-0.29 | $-0.30 | $-0.17 |
| Avg Forecast | - | - | - | - | $0.06 | $0.06 | $0.06 | $0.06 | $0.04 | $0.17 | $-0.06 | $-0.10 | $-0.10 | $-0.09 | $-0.03 | $-0.06 | $-0.02 | $-0.12 | $-0.16 | $-0.20 | $-0.27 | $0.75 |
| High Forecast | - | - | - | - | $0.08 | $0.07 | $0.07 | $0.07 | $0.05 | $0.21 | $-0.05 | $-0.08 | $-0.05 | $-0.07 | $-0.02 | $-0.05 | $0.03 | $-0.10 | $-0.13 | $-0.16 | $-0.21 | $0.75 |
| Low Forecast | - | - | - | - | $0.05 | $0.05 | $0.05 | $0.04 | $0.04 | $0.14 | $-0.07 | $-0.11 | $-0.16 | $-0.11 | $-0.03 | $-0.07 | $-0.09 | $-0.14 | $-0.19 | $-0.24 | $-0.32 | $0.75 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 5.56% | 0.59% | 1.34% | 1.44% | 1.13% | -0.23% |
According to undefined Wall Street analysts, Fennec Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to FENC previous annual EPS of $NaN (undefined).
Fennec Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| MOLN | Molecular Partners | $5.20 | $29.00 | 457.69% | Buy |
| AVTE | Aerovate Therapeutics | $2.66 | $13.00 | 388.72% | Hold |
| ANEB | Anebulo Pharmaceuticals | $1.52 | $6.00 | 294.74% | Buy |
| OLMA | Olema Pharmaceuticals | $8.28 | $28.50 | 244.20% | Buy |
| FENC | Fennec Pharmaceuticals | $4.64 | $15.75 | 239.44% | Buy |
| LRMR | Larimar Therapeutics | $6.08 | $20.33 | 234.38% | Buy |
| ELYM | Eliem Therapeutics | $5.11 | $13.00 | 154.40% | Buy |
| KROS | Keros Therapeutics | $54.14 | $102.60 | 89.51% | Buy |
| HRMY | Harmony Biosciences | $32.79 | $48.86 | 49.01% | Buy |
| EWTX | Edgewise Therapeutics | $31.95 | $45.00 | 40.85% | Buy |
| JANX | Janux Therapeutics | $48.96 | $61.20 | 25.00% | Buy |
| IRON | Disc Medicine | $62.55 | $72.50 | 15.91% | Buy |
| IKNA | Ikena Oncology | $1.70 | $1.33 | -21.76% | Buy |
| CYT | Cyteir Therapeutics | $3.02 | $2.00 | -33.77% | Sell |